Neuroprotective effect of L-DOPA co-administered with the adenosine A 2A receptor agonist CGS 21680 in an animal model of Parkinson's disease

Brain Research Bulletin

Volumn 64, Issue 2, 2004, Pages 155-164

  Agnati, Luigi F ^a   Leo, Giuseppina ^a   Vergoni, Anna Valeria ^a   Martínez, Emili ^b   Hockemeyer, Jörg ^c   Lluis, Carme ^d   Franco, Rafael ^d   Fuxe, Kjell ^e   Ferré, Sergi ^f  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b INST D INVESTIGACIONS B   (Spain)

^c UNIVERSITY OF BONN   (Germany)

^d UNIVERSITY OF BARCELONA   (Spain)

^e KAROLINSKA INSTITUTE   (Sweden)

^f NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

6 Hydroxydopamine; Adenosine A2A receptor; Dopamine D 2 receptor; Dyskinesia; Parkinson's disease; Rat

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE A2A RECEPTOR; DOPAMINE 2 RECEPTOR; HALOPERIDOL; LEVODOPA; OXIDOPAMINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIORAL SCIENCE; CONTROLLED STUDY; EVALUATION; IMMUNOREACTIVITY; INVOLUNTARY MOVEMENT; MALE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SENSITIZATION;

ADENOSINE; ANALYSIS OF VARIANCE; ANIMALS; ANTIPARKINSON AGENTS; APOMORPHINE; CELL COUNT; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE AGONISTS; DRUG THERAPY, COMBINATION; DYSKINESIAS; IMMUNOHISTOCHEMISTRY; LEVODOPA; MALE; OXIDOPAMINE; PARKINSON DISEASE; PHENETHYLAMINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ADENOSINE A2A; STEREOTYPED BEHAVIOR; SYMPATHOLYTICS; TIME FACTORS; TYROSINE 3-MONOOXYGENASE;

EID: 4444298725     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2004.06.003     Document Type: Article

References (58)

1. Agid Y. Levodopa. Is toxicity a myth? Neurology. 57:1998;S46-S51
2. Agnati L.F., Franzen O., Ferré S., Leo G., Franco R., Fuxe K. Possible role of intramembrane receptor-receptor interactions in memory and learning via formation of long-lived heteromeric complexes: focus on motor learning in the basal ganglia. J. Neural Transm. Suppl. 65:2003;1-28
3. Agnati L.F., Tinner B., Staines W.A., Väänänen K., Fuxe K. On the cellular localization and distribution of carbonic anhydrase II immunoreactivity in the rat brain. Brain Res. 676:1995;10-24
4. Andrew R., Watson D.G., Best S.A., Midgley J.M., Wenlong H., Petty R.K. The determination of hydroxydopamines and other trace amines in the urine of parkinsonian patients and normal controls. Neurochem. Res. 18:1993;1175-1177
5. Bara-Jimenez W., Sherzai A., Dimitrova T., Favit A., Bibbiani F., Gillespie M., Morris M.J., Mouradian M.M., Chase T.N. Adenosine A(2A) receptor antagonist treatment of Parkinson's disease. Neurology. 61:2003;293-296
6. Behan W.M., Stone T.W. Enhanced neuronal damage by co-administration of quinolinic acid and free radicals, and protection by adenosine A2A receptor antagonists. Br. J. Pharmacol. 135:2002;1435-1442
7. Bezard E., Ferry S., Mach U., Stark H., Leriche L., Boraud T., Gross C., Sokoloff P. Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nat. Med. 9:2003;762-767
8. Bibbiani F., Oh J.D., Petzer J.P., Castagnoli N. Jr., Chen J.-F., Schwarzschild M.A., Chase T.N. A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease. Exp. Neurol. 184:2003;285-294
9. Blum D., Galas M.C., Pintor A., Brouillet E., Ledent C., Muller C.E., Bantubungi K., Galluzzo M., Gall D., Cuvelier L., Rolland A.S., Popoli P., Schiffmann S.N. A dual role of adenosine A2A receptors in 3-nitropropionic acid-induced striatal lesions: implications for the neuroprotective potential of A2A antagonists. J. Neurosci. 23:2003;5361-5369
10. Bordet R., Ridray S., Carboni S., Diaz J., Sokoloff P., Schwartz J.C. Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proc. Natl. Acad. Sci. U.S.A. 94:1997;3363-3367
11. Calon F., Grondin R., Morissette M., Goulet M., Blanchet P.J., Di Paolo T., Bedard P.J. Molecular basis of levodopa-induced dyskinesias. Ann. Neurol. 47:2000;S70-S78
12. Calon F., Birdi S., Rajput A.H., Hornykiewicz O., Bedard P.J., Di P.T. Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias. J. Neuropathol. Exp. Neurol. 61:2002;186-196
13. Camp D.M., Loeffler D.A., LeWitt P.A. L-DOPA does not enhance hydroxyl radical formation in the nigrostriatal dopamine system of rats with a unilateral 6-hydroxydopamine lesion. J. Neurochem. 74:2000;1229-1240
14. Canals M., Marcellino D., Fanelli F., Ciruela F., De Benedetti P., Goldberg S.R., Fuxe K., Agnati L.A., Woods A.S., Ferré S., Lluis C., Bouvier M., Franco R. Adenosine A2A-dopamine D2 receptor-receptor heteromerization. Qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. J. Biol. Chem. 278:2003;46741-46749
15. Carta A.R., Pinna A., Cauli O., Morelli M. Differential regulation of GAD67, enkephalin and dynorphin mRNAs by chronic-intermittent L-DOPA and A2A receptor blockade plus L-DOPA in dopamine-denervated rats. Synapse. 44:2002;166-174
16. Cassada D.C., Tribble C.G., Long S.M., Kaza A.K., Linden J., Rieger J.M., Rosin D., Kron I.L., Kern J.A. Adenosine A2A agonist reduces paralysis after spinal cord ischemia: correlation with A2A receptor expression on motor neurons. Ann. Thorac. Surg. 74:2002;846-849
17. Cenci M.A., Lee C.S., Bjorklund A. L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin and glutamic acid decarboxylase mRNA. Eur. J. Neurosci. 10:1998;2694-2706
18. Chen J.F., Xu K., Petzer J.P., Staal R., Xu Y.H., Beilstein M., Sonsalla P.K., Castagnoli K., Castagnoli N. Jr., Schwarzschild M.A. Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J. Neurosci. 21:2001;RC143
19. Ferré S., Fredholm B.B., Morelli M., Popoli P., Fuxe K. Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci. 20:1997;482-487
20. Ferré S., Fuxe K., von Euler G., Johansson B., Fredholm B.B. Adenosine-dopamine interactions in the brain. Neuroscience. 51:1992;501-512
21. Ferré S., Popoli P., Gimenez-Llort L., Rimondini R., Muller C.E., Stromberg I., Ogren S.O., Fuxe K. Adenosine/dopamine interaction: implications for the treatment of Parkinson's disease. Parkinsonism Relat. Disord. 7:2001;235-241
22. Fredduzzi S., Moratalla R., Monopoli A., Cuellar B., Xu K., Ongini E., Impagnatiello F., Schwarzschild M.A., Chen J.F. Persistent behavioral sensitization to chronic L-DOPA requires A2A adenosine receptors. J. Neurosci. 22:2002;1054-1062
23. Fuxe K., Stromberg I., Popoli P., Rimondini-Giorgini R., Torvinen M., Ogren S.O., Franco R., Agnati L.F., Ferré S. Adenosine receptors and Parkinson's disease. Relevance of antagonistic adenosine and dopamine receptor interactions in the striatum. Adv. Neurol. 86:2001;345-353
24. Han S.K., Mytilineou C., Cohen G. L-DOPA up-regulates glutathione and protects mesencephalic cultures against oxidative stress. J. Neurochem. 66:1996;501-510
25. Hauser R.A., Hubble J.P., Truong D.D. Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. Neurology. 61:2003;297-303
26. Henry B., Crossman A.R., Brotchie J.M. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Exp. Neurol. 151:1998;334-342
27. Henry B., Crossman A.R., Brotchie J.M. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat. Exp. Neurol. 155:1999;204-220
28. Henry B., Duty S., Fox S.H., Crossman A.R., Brotchie J.M. Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease. Exp. Neurol. 183:2003;458-468
29. Ikeda K., Kurokawa M., Aoyama S., Kuwana Y. Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease. J. Neurochem. 80:2002;262-270
30. Jellinger K., Linert L., Kienzl E., Herlinger E., Youdim M.B. Chemical evidence for 6-hydroxydopamine to be an endogenous toxic factor in the pathogenesis of Parkinson's disease. J. Neural. Transm. Suppl. 46:1995;297-314
31. Kanda T., Jackson M.J., Smith L.A., Pearce R.K., Nakamura J., Kase H., Kuwana Y., Jenner P. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Exp. Neurol. 162:2000;321-327
32. Karcz-Kubicha M., Antoniou K., Terasmaa A., Quarta D., Solinas M., Justinova Z., Pezzola A., Reggio R., Muller C.E., Fuxe K., Goldberg S.R., Popoli P., Ferré S. Involvement of adenosine A1 and A2A receptors in the motor effects of caffeine after its acute and chronic administration. Neuropsychopharmacology. 28:2003;1281-1291
33. Kihara T., Shimohama S., Sawada H., Honda K., Nakamizo T., Kanki R., Yamashita H., Akaike A. Protective effect of dopamine D2 agonists in cortical neurons via the phosphatidylinositol 3 kinase cascade. J. Neurosci. Res. 70:2002;274-282
34. Kudlacek O., Just H., Korkhov V.M., Vartian N., Klinger M., Pankevych H., Yang Q., Nanoff C., Freissmuth M., Boehm S. The human D2 dopamine receptor synergizes with the A2A adenosine receptor to stimulate adenylyl cyclase in PC12 cells. Neuropsychopharmacology. 28:2003;1317-1327
35. Lange K.W., Rausch W.D., Gsell W., Naumann M., Oestreicher E., Riederer P. Neuroprotection by dopamine agonists. J. Neural Transm. Suppl. 43:1994;183-201
36. Lundblad M., Andersson M., Winkler C., Kirik D., Wierup N., Cenci M.A. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur. J. Neurosci. 15:2002;120-132
37. Lundblad M., Vaudano E., Cenci M.A. Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of L-DOPA-induced dyskinesia. J. Neurochem. 84:2003;1398-1410
38. Mura A., Mintz M., Feldon J. Behavioral and anatomical effects of long-term L-dihydroxyphenylalanine (L-DOPA) administration in rats with unilateral lesions of the nigrostriatal system. Exp. Neurol. 177:2002;252-264
39. Nisbet A.P., Foster O.J., Kingsbury A., Eve D.J., Daniel S.E., Marsden C.D., Lees A.J. Preproenkephalin and preprotachykinin messenger RNA expression in normal human basal ganglia and in Parkinson's disease. Neuroscience. 66:1995;361-376
40. Obeso J.A., Olanow C.W., Nutt J.G. Levodopa motor complications in Parkinson's disease. Trends Neurosci. 23:2000;S2-S7
41. O'Neill M.J., Hicks C.A., Ward M.A., Cardwell G.P., Reymann J.M., Allain H., Bentue-Ferrer D. Dopamine D2 receptor agonists protect against ischaemia-induced hippocampal neurodegeneration in global cerebral ischaemia. Eur. J. Pharmacol. 352:1998;37-46
42. Pedrazzi P., Cattaneo L., Valeriani L., Boschi S., Cocchi D., Zoli M. Hypothalamic neuropeptide Y and galanin in overweight rats fed a cafeteria diet. Peptides. 19:1998;157-165
43. Petzer J.P., Steyn S., Castagnoli K.P., Chen J.F., Schwarzschild M.A., Van der Schyf C.J., Castagnoli N. Inhibition of monoamine oxidase B by selective adenosine A2A receptor antagonists. Bioorg. Med. Chem. 11:2003;1299-1310
44. Pezzella A., d'Ischia M., Napolitano A., Misuraca G., Prota G. Iron-mediated generation of the neurotoxin 6-hydroxydopamine quinone by reaction of fatty acid hydroperoxides with dopamine: a possible contributory mechanism for neuronal degeneration in Parkinson's disease. J. Med. Chem. 40:1997;2211-2216
45. Picconi B., Centonze D., Hakansson K., Bernardi G., Greengard P., Fisone G., Cenci M.A., Calabresi P. Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat. Neurosci. 6:2003;501-506
46. Pinna A., Fenu S., Morelli M. Motor stimulant effects of the adenosine A2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats. Synapse. 39:2001;233-238
47. Popoli P., Pintor A., Domenici M.R., Frank C., Tebano M.T., Pezzola A., Scarchilli L., Quarta D., Reggio R., Malchiodi-Albedi F., Falchi M., Massotti M. Blockade of striatal adenosine A2A receptor reduces, through a presynaptic mechanism, quinolinic acid-induced excitotoxicity: possible relevance to neuroprotective interventions in neurodegenerative diseases of the striatum. J. Neurosci. 22:2002;1967-1975
48. Rodriguez M., Barroso-Chinea P., Abdala P., Obeso J., Gonzalez-Hernandez Dopamine cell degeneration induced by intraventricular administration of 6-hydroxydopamine in the rat: similarities with cell loss in parkinson's disease. Exp. Neurol. 169:2001;163-181
49. Rosin D.L., Robeva A., Woodard R.L., Guyenet P.G., Linden J. Immunohistochemical localization of adenosine A2A receptors in the rat central nervous system. J. Comp. Neurol. 401:1998;163-186
50. Sauer R., Maurinsh J., Reith U., Fulle F., Klotz K.N., Muller C.E. Water-soluble phosphate prodrugs of 1-propargyl-8-styrylxanthine derivatives, A(2A)-selective adenosine receptor antagonists. J. Med. Chem. 43:2000;440-448
51. Sawada H., Ibi M., Kihara T., Urushitani M., Akaike A., Kimura J., Shimohama S. Dopamine D2-type agonists protect mesencephalic neurons from glutamate neurotoxicity: mechanisms of neuroprotective treatment against oxidative stress. Ann. Neurol. 44:1998;110-119
52. Sternberger L.A., Sternberger N.H. The unlabeled antibody method: comparison of peroxidase-antiperoxidase with avidin-biotin complex by a new method of quantification. J. Histochem. Cytochem. 34:1986;599-605
53. Stromberg I., Popoli P., Muller C.E., Ferré S., Fuxe K. Electrophysiological and behavioural evidence for an antagonistic modulatory role of adenosine A2A receptors in dopamine D2 receptor regulation in the rat dopamine-denervated striatum. Eur. J. Neurosci. 12:2000;4033-4037
54. Tel B.C., Zeng B.Y., Cannizzaro C., Pearce R.K., Rose S., Jenner P. Alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA ropinirole or bromocriptine correlate with dyskinesia induction in MPTP-treated common marmosets. Neuroscience. 115:2002;1047-1058
55. Ungerstedt U. Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol. Scand. Suppl. 367:1971;69-93
56. Vortherms T.A., Watts V.J. Sensitization of neuronal A2A adenosine receptors after persistent D2 dopamine receptor activation. J. Pharmacol. Exp. Ther. 308:2004;221-227
57. Wamsley J.K., Gehlert D.R., Filloux F.M., Dawson T.M. Comparison of the distribution of D-1 and D-2 dopamine receptors in the rat brain. J. Chem. Neuroanat. 2:1989;119-137
58. Yao L., Arolfo M.P., Dohrman D.P., Jiang Z., Fan P., Fuchs S., Janak P.H., Gordon A.S., Diamond I. Betagamma dimers mediate synergy of dopamine D2 and adenosine A2 receptor-stimulated PKA signaling and regulate ethanol consumption. Cell. 109:2002;733-743